Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1058 - Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 study


08 Oct 2016


Poster Display


Jia Chen


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


J. Chen1, J. Xiong2, J. Wang3, L. Zheng4, Y. Gao5, Z. Guan6

Author affiliations

  • 1 Department Of Oncology, Jiangsu Cancer Institute and Hospital, 210000 - Nanjing/CN
  • 2 Department Of Oncology, 1st Affiliated Hospital of Nanchang Universi, Nanchang/CN
  • 3 Department Of Oncology, Shanghai Changzheng Hospital, Shanghai/CN
  • 4 Department Of Oncology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai/CN
  • 5 Medical Affairs, Shanghai Roche Pharmaceuticals Ltd, Shanghai/CN
  • 6 Department Of Oncology, Cancer Centre Sun Yat-Sen University, Guangzhou/CN


Abstract 1058


This study presents a re-analyses of the efficacy and safety data from the ML17032 trial to confirm the non-inferiority and test the potential superiority of a capecitabine (Xeloda®)/ cisplatin (XP) combination over a 5-fluorouracil (5-FU)/cisplatin (FP) regimen as first-line treatment for advanced gastric cancer (AGC) in Chinese patients.


In this open label phase III trial, patients with advanced gastric cancer (Stage IIIA-IV) with or without metastases were randomized 1:1 to receive Cisplatin (80mg/m2/day IV day 1) with either Capecitabine (1000mg/m2/day PO BID, days1-14) (XP) or 5-FU (800mg/m2/day continuous IV days 1-5) (FP) every 3 weeks. The primary objective was to confirm the non -inferiority of XP over FP for progression free survival (PFS).


A total of 126 Chinese patients (XP-62, FP-64; 75.4% male, median age 55.5 years) were enrolled as the intent to treat population. The per-protocol population consisting of 105 patients (XP-51, FP-54; 64.7% male) served as the primary analysis group for establishing non-inferiority. Median PFS in the XP and FP groups was 7.2 and 4.5 months respectively. The primary efficacy endpoint of PFS was met with an adjusted hazard Ratio (HR) of 0.52 (95% Confidence interval [CI]: [0.32-0.83], p = 0.006). Unadjusted HR for PFS in ITT population was 0.63 (95% CI: [0.42-0.94], p = 0.022). Among secondary efficacy endpoints OS (adjusted HR 0.61 [0.37-1.01], p = 0.053) and TTF (HR 0.54, [0.35, 0.84], p = 0.006) demonstrated a trend towards superiority of XP over FP. Drug exposure was similar among 2 groups in the safety population (XP-58, FP-62, 68.3% male). The most frequent drug related Grade 3/4 AEs were neutropenia (XP-20.7%; FP-17.7%) and gastrointestinal disorders (XP-19.0%; FP-19.4%). The overall incidence of grade 3/4 AEs (XP-43.1%; FP-46.8%), SAEs (XP-1.7%; FP-3.2%), and AEs related to treatment discontinuation (XP-10.3%; FP-16.1%) were comparable among the 2 groups.


XP may demonstrate superiority for PFS and TTF compared to FP in the first-line treatment of Chinese patients with AGC and had a similar safety profile to FP.

Clinical trial identification

ClinicalTrials.gov NCT02563054.

Legal entity responsible for the study



This study was sponsored by Shanghai Roche Pharmaceuticals Ltd, China (ML 17032)


Y. Gao: Employee of Shanghai Roche Pharmaceuticals Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings